Tirzepatide denied as non-formulary by Blue Cross Blue Shield?

Blue Cross Blue Shield's specific coverage criteria for tirzepatide are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why BCBS Denies Tirzepatide as Non-Formulary

Blue Cross Blue Shield places tirzepatide on formulary tiers that vary by regional plan and plan design. A non-formulary denial means your specific BCBS plan either does not include tirzepatide on the covered drug list at any tier, places it on a specialty tier requiring PA and step-therapy, or excludes it for a particular indication. Non-formulary denials are coverage-design decisions — not clinical determinations — and they are routinely overturned through the formulary exception process or on appeal when the prescriber documents that formulary alternatives are clinically inappropriate.

Because BCBS is a federation of regional plans, formulary composition varies significantly by state. Confirm your plan's exact formulary and exception process with the customer service number on your insurance card.

## Your Federal Appeal Rights

• ACA §2719 / External Review: After exhausting internal appeals, ACA-compliant plans must offer IRO external review. The external-review request window is typically around four months from the final internal denial — verify the exact deadline from your denial letter.
• ERISA §503 Full-and-Fair Review: ERISA plans must disclose the formulary exception criteria and allow submission of clinical evidence.
• Formulary Exception (Parallel Pathway): File a formulary exception request simultaneously with the appeal. A successful exception is faster than a full appeal and achieves the same coverage outcome.
• Expedited Review: Available for urgent clinical situations; request it simultaneously with all other filings.

## Appeal and Exception Timeline

1. File the formulary exception request and the internal appeal simultaneously — do not wait for one to conclude before starting the other. 2. The exception request should be prescriber-driven and cite the clinical reason each preferred formulary alternative is inappropriate for this patient. 3. Internal appeal decisions are typically required within 30 days (pre-service) or 60 days (post-service). 4. If both are denied, proceed immediately to IRO external review.

## Documentation to Gather

• Prescriber formulary exception / appeal letter: A combined letter addressing each preferred formulary alternative by name and explaining the specific clinical reason it is not appropriate for this patient — inadequate response in prior trial, documented intolerance, clinical contraindication, or a distinct clinical feature that makes tirzepatide the appropriate choice.
• Prior formulary-alternative trial records: Prescription fills, pharmacy records, and chart notes documenting each formulary alternative that was tried, with dates, duration, and clinical outcome.
• Diagnosis and clinical severity documentation: Chart notes and lab results confirming the diagnosis and the clinical basis for treatment.
• FDA label alignment: Confirmation that the prescribed indication aligns with tirzepatide's FDA-approved label.

## Criteria-Mapping Structure

Obtain BCBS's formulary exception criteria for your regional plan. For each listed requirement, provide a specific document or prescriber attestation. The core of a successful non-formulary appeal is a clear, named account of why each preferred tier alternative is clinically inappropriate for this specific patient — not a generic preference for tirzepatide. The more granular and chart-specific this account is, the harder it is for BCBS to deny again on the same grounds, and the stronger the record for external review.